Boehringer vs Facebook Social Media Socialism
Boehringer-Ingelheim (BI) stands out in its attempt to stand out from the social(ist) cookie-cutter crowd of pharma FB pages. Shows what you can do with dedicated resources and creativity.
Pharma Marketing News Vol. 10, No. 14: 22 September 2011
Welcome to Volume 10, Issue #14 (22 SEPTEMBER 2011) of Pharma Marketing News.
Boehringer vs Facebook Social Media Socialism
Boehringer-Ingelheim (BI) stands out in its attempt to stand out from the social(ist) cookie-cutter crowd of pharma FB pages. Shows what you can do with dedicated resources and creativity.
New Big Pharma Economies of Scale
How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?
New Big Pharma Economies of Scale
How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?
Orphan Drugs Now “Where the Money Is,” Says Willie Sutton’s Ghost
Why do pharma companies bother developing drugs for for a disorder affecting fewer than 200,000 people? Willie Sutton's ghost may have the answer.
Orphan Drugs Now “Where the Money Is,” Says Willie Sutton’s Ghost
Why do pharma companies bother developing drugs for for a disorder affecting fewer than 200,000 people? Willie Sutton's ghost may have the answer.
Pharma’s Physician Bailout
The pharmaceutical industry has been very generous in making payments to physicians. Last year (2010), for example, a mere dozen pharmaceutical companies paid $760 million to physicians and other health care providers for consulting, speaking, research and expenses. On average, how much do you think that comes to for every physician in the U.S.?
Pharma’s Physician Bailout
The pharmaceutical industry has been very generous in making payments to physicians. Last year (2010), for example, a mere dozen pharmaceutical companies paid $760 million to physicians and other health care providers for consulting, speaking, research and expenses. On average, how much do you think that comes to for every physician in the U.S.?
Vast Majority of Drug Ads in Leading Medical Journals Don’t Pass MDs’ Sniff Test!
A study led by Mount Sinai School of Medicine researchers of 192 pharmaceutical advertisements (83 full unique advertisements) in biomedical journals found that only 18 percent (15) were compliant with Food and Drug Administration (FDA) guidelines, and over half failed to quantify serious risks including death.
